Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Development of formulations of sorafenib tosylate for improved biopharmaceutical potential
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Poster
- By: SHARMA, Teenu (Panjab University, University institute of Pharmaceutical sciences)
- Co-author(s): Teenu Sharma: University institute of Pharmaceutical sciences, Panjab University, Chandigarh, India
Atul Jain: UGC-CoE ANNN, Panjab University, Chandigarh, India
O P Katare: University institute of Pharmaceutical sciences, Panjab University, Chandigarh, India
Bhupinder Singh: UGC-CoE ANNN, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
Sorafenib tosylate, BCS class II anticancer drug, exhibits low oral bioavailability (8%) ostensibly owing to poor aqueous solubility, high first-pass effect and P-gp efflux.
MethodsThe patient-centric quality target product profile (QTPP) and critical quality attributes (CQAs) were earmarked. Ishikawa Fish-bone diagram was constructed.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 13 May 2019